Scope of Reporting
Corporate Responsibility Materiality
The content of this report is based on two key factors – its importance to stakeholders and its potential to influence business strategy. Pfizer aims to address critical issues most relevant for colleagues and external stakeholders. These include the following topics that influence the sustainability of the organization:
- Patient Access.
- Environmental Sustainability.
- Culture and Human Capital.
- Employee Health & Safety.
- Quality, Manufacturing and Supply Chain Management.
- Ethics and Compliance.
- United Nations (UN) Sustainable Development Goals (SDGs).
Corporate Responsibility Management
Improving Our Access to Medicine Offerings
Every two years, the Access to Medicine Index (ATMi) assesses the top 20 research-based pharmaceutical companies on their strategies to enable greater access to essential medicines, vaccines and diagnostics in low- and middle-income countries. The Index ranks these companies according to their efforts in several areas, including research and development, capacity building, compliance and others.
In 2018, Pfizer improved its overall ranking by three places, jumping to 11th place from 14th in 2016. Theperformance increase was credited to the introduction of our access to medicine strategy, strong compliance efforts and continued commitment to health care system strengthening. Pfizer obtained improvements in the following categories:
- Market Influence & Compliance.
- Capacity Building.
- General Access to Medicine Management.
- Pricing, Manufacturing & Distribution.
Pfizer supports the goals of the ATMi and recognizes the importance of having a tool that attempts to measure access to medicines and vaccines. Our improved ranking to number 11 on the list is a confirmation of the significant efforts we make to increase access to our medicines and vaccines, including advancements in our pipeline, the development and implementation of equitable pricing strategies and advancing our donation programs.
Our multiple approaches to social investments apply novel, well-researched and sustainable approaches to meet the health needs of the underserved while investing in the health of our communities and our business. We strive to make the best use of Pfizer's resources – our people, products and funding – to help build health care capacity and expand access to medicines and vaccines.
Global Reporting Frameworks
Pfizer continues to evaluate our approach to reporting, including reference to several existing, globally recognized external frameworks. These include the Global Reporting Initiative (GRI), the Task Force for Climate-Related Financial Disclosures and the International Integrated Reporting Council. We relied on elements of each framework in developing this year's Annual Review, while formally adhering to none in its entirety. We included GRI Reference Tables as a tool to help readers more readily locate relevant information within this review and across Pfizer's web-based resources.
Pfizer also considers elements of other ESG indices and sustainability indicators – in particular, the ATMi and the UN SDGs (also known as the Global Goals). Throughout this review, you will see the Global Goals icons alongside various efforts to highlight the work we are doing across Pfizer to meet these goals by 2030.
As a signatory to the UN Global Compact – a document that asks companies to embrace universal principles and to partner with the UN – we submit an annual communication to the UN on our progress made toward achieving the Global Goals.View the full progress update.
Read more about ourCorporate and Shareholder Information, including Forward-Looking Statements.